Certolizumab Pegol Treatment in Three Patients With Takayasu Arteritis
Copyright © 2019, Turkish League Against Rheumatism..
Although glucocorticoids are the mainstay of treatment in Takayasu arteritis (TA), anti-tumor necrosis factor agents are other treatment options in refractory disease. The onset of TA is generally observed in females of reproductive age. Certolizumab pegol (CZP) lacks a fragment crystallizable region and this gives advantage of minimal transfer through the placenta, which makes CZP a safer option in pregnancy. Although there are case reports and trials about use of infliximab, etanercept, and adalimumab in TA, there are scarce data about use of CZP. In this article, we present three TA cases treated with CZP. While two patients benefited from CZP, one patient was refractory to CZP.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Archives of rheumatology - 34(2019), 3 vom: 01. Sept., Seite 357-362 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ataş, Nuh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-tumor necrosis factor |
|---|
| Anmerkungen: |
Date Revised 30.09.2020 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.5606/ArchRheumatol.2019.7177 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM302055495 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM302055495 | ||
| 003 | DE-627 | ||
| 005 | 20231225105915.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5606/ArchRheumatol.2019.7177 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1006.xml |
| 035 | |a (DE-627)NLM302055495 | ||
| 035 | |a (NLM)31598605 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ataş, Nuh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Certolizumab Pegol Treatment in Three Patients With Takayasu Arteritis |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.09.2020 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2019, Turkish League Against Rheumatism. | ||
| 520 | |a Although glucocorticoids are the mainstay of treatment in Takayasu arteritis (TA), anti-tumor necrosis factor agents are other treatment options in refractory disease. The onset of TA is generally observed in females of reproductive age. Certolizumab pegol (CZP) lacks a fragment crystallizable region and this gives advantage of minimal transfer through the placenta, which makes CZP a safer option in pregnancy. Although there are case reports and trials about use of infliximab, etanercept, and adalimumab in TA, there are scarce data about use of CZP. In this article, we present three TA cases treated with CZP. While two patients benefited from CZP, one patient was refractory to CZP | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Anti-tumor necrosis factor | |
| 650 | 4 | |a Takayasu arteritis | |
| 650 | 4 | |a certolizumab pegol | |
| 650 | 4 | |a pregnancy | |
| 700 | 1 | |a Varan, Özkan |e verfasserin |4 aut | |
| 700 | 1 | |a Babaoğlu, Hakan |e verfasserin |4 aut | |
| 700 | 1 | |a Satiş, Hasan |e verfasserin |4 aut | |
| 700 | 1 | |a Bilici Salman, Reyhan |e verfasserin |4 aut | |
| 700 | 1 | |a Tufan, Abdurrahman |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archives of rheumatology |d 2016 |g 34(2019), 3 vom: 01. Sept., Seite 357-362 |w (DE-627)NLM285452444 |x 2618-6500 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2019 |g number:3 |g day:01 |g month:09 |g pages:357-362 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5606/ArchRheumatol.2019.7177 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2019 |e 3 |b 01 |c 09 |h 357-362 | ||